

**pH MANAGEMENT DURING HYPOTHERMIC  
CARDIOPULMONARY BYPASS DOES NOT INFLUENCE  
CEREBRAL OXYGEN CONSUMPTION**

JM Murkin MD,FRCP; M Sharpe MD,FRCP; JK  
Farrar PhD

Departments of Anaesthesia, and Clinical  
Neurological Sciences, University Hospital,  
University of Western Ontario, London,  
Ontario. Supported by PSI Grant 89-31.

Controversy regarding optimal pH management techniques during hypothermic cardiopulmonary bypass (CPB), includes reports of disproportionate decreases in cerebral metabolic rate for oxygen (CMRO<sub>2</sub>) during pH-stat management at 27°C,<sup>1</sup> vs preservation of cerebral flow/metabolism coupling with proportionate decreases in cerebral blood flow (CBF) reported during alpha-stat pH management.<sup>2</sup> The following study was designed to prospectively assess the influence of pH management on CBF and CMRO<sub>2</sub> in patients during hypothermic CPB.

**Methods:** After obtaining institutional ethics committee approval and written informed consent, 5 patients, mean age 58±14 yr undergoing hypothermic CPB, had CBF measured using <sup>133</sup>Xe clearance. Using a jugular catheter for sampling effluent cerebral venous blood, CMRO<sub>2</sub> was determined as the product of CBF and cerebral arterial-

venous oxygen content difference. Once a stable nasopharyngeal temperature had been obtained during CPB, patients were randomly assigned to either alpha-stat or pH-stat management techniques and CBF and CMRO<sub>2</sub> were measured. Following this, the alternate pH management technique was employed and CBF and CMRO<sub>2</sub> were remeasured after a minimum 5 min equilibration period. Data were analyzed using a paired t-test with p < 0.05 required for significance.

**Results:** There were no significant differences in temperature or mean arterial pressure between the two measurement periods. Mean temperature corrected PaCO<sub>2</sub> was 31.6±2.6 mmHg during alpha-stat and 40.8±3.8 mmHg during pH-stat pH management (p<0.05). Mean CBF was significantly higher in the pH-stat 32.9±5.2 ml.100g<sup>-1</sup>.min<sup>-1</sup>) vs a significant alpha-stat (19±2.2 ml.100g<sup>-1</sup>.min<sup>-1</sup>) groups (p<0.05). However, there was no significant difference in CMRO<sub>2</sub> between the two groups (0.61±0.17 vs 0.57±0.27 ml.100g<sup>-1</sup>.min<sup>-1</sup>, respectively).

**Discussion:** This study is consistent with reports demonstrating alterations in CBF, but no differences in CMRO<sub>2</sub>, during alpha-stat vs pH-stat pH management,<sup>2</sup> but does not support the concept of decreases in CMRO<sub>2</sub> resulting from differences in pH management<sup>1</sup> over this range of PaCO<sub>2</sub> values.

**References:** 1.Rogers et al. Anesth Analg 67:S187, 1988. 2.Murkin et al. Anesth Analg 66:825-32,1987.

## A118

**Title:** PHOSPHOLIPASE A<sub>2</sub> ACTIVITY AND  
PROSTAGLANDIN LEVELS DURING  
CARDIAC SURGERY.

**Authors:** H.Nakamura, M.D.,D.Philbin, M.D.,  
M.Peterson, F.deBros, M.D.,  
J.V. Bonventre, M.D., Ph.D.

**Affiliation:** Depts. Anes. and Medicine,  
Harvard Med. School at Mass.  
Gen. Hosp., Boston, MA 02114  
and Dept. Pediatrics, Tufts  
University, Boston, MA 02111

Prostaglandin levels (TxB<sub>2</sub>, 6-Keto) are elevated during CPB.<sup>1</sup> Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) is an enzyme involved in release of free<sup>2</sup> fatty acids necessary for prostaglandin production. This study examined PLA<sub>2</sub> activity and its relationship to prostaglandin levels during cardiac surgery.

Twelve adult patients undergoing CABG were studied with institutional approval and informed consent. Samples for measurement of PLA<sub>2</sub>, TxB<sub>2</sub> and 6-Keto were obtained before induction,<sup>2</sup> after incision, before and after heparin (3 mg/kg), at 15,30 and 60 min. of CPB, before and after protamine, and at end of operation.<sup>2</sup> PLA<sub>2</sub> was measured by the method of Ballou<sup>2</sup>; TxB<sub>2</sub> and 6-Keto by radioimmunoassay.

No significant changes were detected until heparin administration. With this,

PLA<sub>2</sub> activity rose significantly (0.13±0.02 to 0.46±0.09 pmol/min/mg - p < 0.05) and was accompanied by a significant rise in 6-Keto (96±28 to 454±92 pg/ml - p < 0.05). These remained elevated until after CPB. Protamine administration produced significant decreases (0.50±0.07 to 0.23±0.05 p.mol/min/mg - p < 0.05 and 370±100 to 200±47 pg/ml - p < 0.05 respectively). TxB<sub>2</sub> levels did not increase until CPB (124±20 to 197±36 pg/ml - p < 0.05), but remained elevated after protamine (195±32 to 240±49 pg/ml) reversing the TxB<sub>2</sub>/6-Keto ratio (0.94±0.29 to 1.85±0.57)<sup>2</sup>.

These data demonstrate that heparin administration produces significant increases in PLA<sub>2</sub> activity associated with increases in 6-Keto but not TxB<sub>2</sub> levels. The increase in TxB<sub>2</sub> occurs with CPB and may be due to a number of factors (cellular destruction, etc.). While protamine administration reduces PLA<sub>2</sub> activity and returns 6-Keto toward control levels, it has no effect on TxB<sub>2</sub> levels. The reversal of the TxB<sub>2</sub>/6-Keto ratio by protamine may be a factor in the deleterious effects sometimes associated with its administration.

**References**  
1. J Thorac Cardiovasc Surg 84:250-256,1982  
2. Proc Nat'l Acad Sci USA 80:5203-52, 1983